Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection

Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents, Journal of Hematology & Oncology

Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

Pharmaceutics, Free Full-Text

The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy - The Lancet Gastroenterology & Hepatology

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

PDF) Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

WO2016087994A1 - Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment - Google Patents

Cancers, Free Full-Text

Extracellular matrix and its therapeutic potential for cancer treatment

Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells

Genes, Free Full-Text